Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5977733 | 1.00 | SLC29A1 (0.44) | SLC29A1SLC5A2CYP1A2ADORA2AADORA2B | |
| SCHEMBL12718329 | 0.90 | CYP1A2 (0.45) | SLC29A1SLC5A2CYP1A2ADORA2AADORA2B | |
| SCHEMBL5979168 | 0.85 | CYP1A2 (0.38) | SLC29A1CYP1A2ADORA2AADORA2B | |
| SCHEMBL5979165 | 0.85 | CYP1A2 (0.38) | SLC29A1CYP1A2ADORA2AADORA2B | |
| SCHEMBL7962505 | 0.84 | CYP1A2 (0.36) | SLC29A1SLC5A2CYP1A2ADORA2AADORA2B | |
| SCHEMBL19418518 | 0.84 | PRMT5 (0.36) | SLC5A2P2RY6P2RY2 | |
| SCHEMBL1596825 | 0.83 | CYP1A2 (0.35) | SLC29A1SLC5A2CYP1A2P2RY6SLC5A1 | |
| SCHEMBL19953912 | 0.82 | LMNA (0.47) | SLC29A1SLC5A2CYP1A2ADORA2AADORA2B | |
| SCHEMBL13435043 | 0.82 | LMNA (0.47) | SLC29A1SLC5A2CYP1A2ADORA2AADORA2B | |
| SCHEMBL11993811 | 0.82 | LMNA (0.47) | SLC29A1SLC5A2CYP1A2ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212339-B1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7037646-B1 | Amine-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-6624294-B2 | Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside | ISIS PHARMACEUTICALS, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-0728139-B1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | IONIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1212339-A4 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1212339-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6403779-B1 | DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION | ISIS PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6277982-B1 | REACTING CARBOHYDRATE, OLIGONUCLEOTIDE, NUCLEOTIDE OR NUCLEOSIDE WITH CYCLIC SULFATE; PRODUCTION OF OLIGONUCLEOTIDES WITH IMPROVED HYBRIDIZATION AFFINITY AND NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| WO-2001014400-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| US-6147200-A | NUCLEOSIDES FOR SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES HAVING INCREASED NUCLEASE RESISTANCE AND BETTER BINDING AFFINITY; DIAGNOSIS; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0728139-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995006659-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | NSUN2, NT5C3B, RNGTT | SLC29A1 201/4885SLC5A2 2266/4885CYP1A2 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.